Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

Lignende værker

• Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
  af: Steigbigel, Roy T., et al.
  Udgivet: (2010)
• Association between First-Year Virologic Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection
  af: Eron, Joseph J., et al.
  Udgivet: (2014)
• Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
  af: Rockstroh, J, et al.
  Udgivet: (2010)
• Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study
  af: Gatell, Jose M., et al.
  Udgivet: (2010)
• Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
  af: Lennox, Jeffrey L., et al.
  Udgivet: (2010)